My Locations
Gary C. Werths Building at Siteman Cancer Center
Siteman Cancer Center at Northwest HealthCare
Expertise & Training
Clinical Expertise
As a member of our head and neck and thyroid specialist team, Dr. Harbison cares for patients with benign tumors of the head and neck, cancers of unknown primary origin, head and neck cancers, hypopharyngeal cancer, laryngeal cancer, melanoma of the head and neck, nasal cancer, neck masses, oropharyngeal and pharyngeal cancers, parotid and submandibular gland tumors, salivary gland cancer, sarcoma of the head and neck, sinus cancer, skin cancer, thyroid cancer and other thyroid and parathyroid diseases. He also specializes in head and neck surgery, radiofrequency ablation of thyroid nodules, transoral robotic surgery (TORS), and transoral endocrine surgery for thyroid and parathyroid conditions.
Primary Academic Title
Assistant Professor of Otolaryngology, WashU Medicine
Board Certification
- 2022: American Board of Otolaryngology - Head and Neck Surgery
- 2025: Adult Complex Thyroid/Parathyroid Surgery Focused Practice Designation
Training
- 2013 - 2014: Intern, General Surgery, University of Washington, Seattle, WA
- 2015 - 2017: T32 Postdoctoral Research Fellowship, University of Washington, Seattle, WA
- 2014 - 2020: Resident, Otolaryngology - Head & Neck Surgery, University of Washington, Seattle, WA
- 2020 -2021: Postdoctoral Research Fellowship, Immunometabolism, Johns Hopkins University School of Medicine, Baltimore, MD
- 2021 - 2022: Fellowship, Head and Neck Surgical Oncology, Johns Hopkins University School of Medicine, Baltimore, MD
Education
- 2009: BS, University of Denver, Denver CO
- 2013: MD, University of Colorado - Anschutz Medical Campus, Aurora, CO
- 2017: MS, University of Washington, Seattle, WA
Research & Select Publications
Research Interest
My research is centered on understanding how tumor polyamine metabolism shapes anti-tumor immune responses. Polyamines are critical immune regulators that play a key role in maintaining homeostasis, but tumors upset this balance resulting in dysregulation of immunity. We are developing novel tools to study the interactions between immune cells and metabolites in the tumor microenvironment. Our group is also developing novel therapeutics targeting cancer cell metabolism to enhance anti-tumor immunity.
Research Publications